Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

This publication has 48 references indexed in Scilit:

• PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas
  Pigment Cell & Melanoma Research, 2010
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
  Nature, 2010
• Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
  New England Journal of Medicine, 2010
• A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
  Cell, 2010
• RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
  Nature, 2010
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
  Published by Elsevier ,2010
• CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
  Oncogene, 2008
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
  Proceedings of the National Academy of Sciences, 2008
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
  Science, 2007
• Mutations of the BRAF gene in human cancer
  Nature, 2002